U.K. May Turn To “Value-Based” Drug Pricing In Place Of Price Limits
Executive Summary
The British Department of Health has notified drug companies that it is ending the current Pharmaceutical Pricing Regulation Scheme as of Aug. 31 and will examine other approaches, such as "value-based" drug pricing
You may also be interested in...
Serious Adverse Events Consortium Expects Data On Genetic Variants Shortly
Initial data generated by the Serious Adverse Events Consortium with regard to DNA variants associated with drug-related serious skin rash will be available at the end of 2008 or in January 2009, SAEC executive director Arthur Holden predicts
Serious Adverse Events Consortium Expects Data On Genetic Variants Shortly
Initial data generated by the Serious Adverse Events Consortium with regard to DNA variants associated with drug-related serious skin rash will be available at the end of 2008 or in January 2009, SAEC executive director Arthur Holden predicts
U.K. Drug Spending Plan Balances 5% Cut With Increased Access
The U.K. National Health Service could save approximately £310 million in branded drug costs in 2009 under a preliminary agreement between the government and the pharmaceutical industry